eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 12
Clinical research

Lipid-lowering and anti-inflammatory effects of omega 3 ethyl esters and krill oil: a randomized, cross-over, clinical trial

Arrigo F.G. Cicero, Martina Rosticci, Martino Morbini, Marcella Cagnati, Elisa Grandi, Angelo Parini, Claudio Borghi

Arch Med Sci 2016; 12, 3: 507–512
Online publish date: 2016/05/18
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Introduction: Polyunsaturated fatty acids (PUFAs) derived from different sources could have different lipid-lowering effects in humans. The main aim of our study was to compare the short-term triglyceride-lowering efficacy of krill oil and purified omega 3 ethyl ester PUFAs in mildly overweight hypertriglyceridemic subjects.

Material and methods: This double-blind, randomized clinical trial was carried out in 25 moderately hypertriglyceridemic subjects (TG = 150–500 mg/dl). After a 4-week run-in, participants were allocated to treatment with similar pills containing omega 3 ethyl ester PUFAs 1000 mg twice a day vs. krill oil 500 mg twice a day. After 4 weeks of treatment, participants were asked to observe a 4-week wash-out period, and they were then assigned to the alternative treatment for a further period of 4 weeks.

Results: Although both PUFA sources were able to improve TG plasma levels, esterified omega 3 PUFAs were more efficacious than krill oil (p < 0.05). Nonetheless, only krill oil treatment was able to significantly improve high-density lipoprotein cholesterol and apolipoprotein AI levels, compared to both baseline (p < 0.05) and end of treatment with esterified omega 3 PUFAs (p < 0.05) values. Both treatments were able to significantly reduce high-sensitivity C-reactive protein (hs-CRP) levels from the baseline (p < 0.05), but krill oil improved it more efficaciously than esterified omega 3 PUFAs (p < 0.05).

Conclusions: Krill oil has lipid-lowering effects comparable with those obtained through a 4-fold higher dose of purified omega 3 ethyl ester PUFAs in mildly overweight hypertriglyceridemic subjects, while more efficaciously reducing hs-CRP.

krill oil, eicosapentaenoic acid, docosahexaenoic acid, omega 3 fatty acids, hyperlipidemia, inflammation

Cicero AF, De Sando V, Parini A, Borghi C. Polyunsaturated fatty acids application in internal medicine: beyond the established cardiovascular effects. Arch Med Sci 2012; 8: 784-93.
Cicero AF, Ertek S, Borghi C. Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. Curr Vasc Pharmacol 2009; 7: 330-7.
Cicero AF, Morbini M, Borghi C. Do we need “new” omega 3 polyunsaturated fatty acids formulations? Exp Opin Pharmacother 2014; 4: 1-4.
Ramprasath VR, Eyal I, Zchut S, Jones PJH. Enhanced increase of omega 3 index in healthy individuals with response to 4 week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health Dis 2013; 12: 178.
Naguib YM. Antioxidant activities of astaxanthin and related carotenoids. J Agric Food Chem 2000; 48: 1150-4.
Ulven SM, Kirkhus B, Lamglait A, et al. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids 2011; 46: 37-46.
Cicero AF, Derosa G, Parini A, et al. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res 2013; 33: 622-8.
Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136-41.
Derosa G, Limas CP, Macías PC, Estrella A, Maffioli P. Dietary and nutraceutical approach to type 2 diabetes. Arch Med Sci 2014; 10: 336-44.
Mariscalco G, Sarzi Braga S, Banach M, et al. Preoperative n-3 polyunsatured fatty acids are associated with a decrease in the incidence of early atrial fibrillation following cardiac surgery. Angiology 2010; 61: 643-50.
Banach M, Serban C, Aronow WS, et al. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol 2014; 46: 947-61.
Superko HR, Superko AR, Lundberg GP, et al. Omega-3 fatty acid blood levels clinical significance update. Curr Cardiovasc Risk Rep 2014; 8: 407.
Ghasemifard S, Turchini GM, Sinclair AJ. Omega-3 long chain fatty acid “bioavailability”: a review of evidence and methodological considerations. Prog Lipid Res 2014; 56C: 92-108.
Bunea R, El Farrah K, Deutsch L. Evaluation of the effects of neptune krill oil on the clinical course of hyperlipidemia. Alt Med Rev 2004; 9: 420-8.
Calder PC. Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta 2015; 1851: 469-84.
Deutsch L. Evaluation of the effect of Neptune Krill Oil on chronic inflammation and arthritic symptoms. J Am Coll Nutr 2007; 26: 39-48.
Banni S, Carta G, Murru E, et al. Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. Nutr Metab 2011; 8: 7.
Konagai C, Yanagimoto K, Hayamizu K, Han L, Tsuji T, Koga Y. Effects of krill oil containing n-3 polyunsaturated fatty acids in phospholipid form on human brain function: a randomized controlled trial in healthy elderly volunteers. Clin Interv Aging 2013; 8: 1247-57.
Ferramosca A, Zara V. Modulation of hepatic steatosis by dietary fatty acids. World J Gastroenterol 2014; 20: 1746-55.
Cicero AF, Colletti A. Krill oil: evidence of a new source of polyunsaturated fatty acids with high bioavailability. Clin Lipidol 2015; 10: 1-4.
Sikora J, Kostka B, Marczyk I, Krajewska U, Chałubiński M, Broncel M. Effect of statins on platelet function in patients with hyperlipidemia. Arch Med Sci 2013; 9: 622-8.
Guardado-Mendoza R, Prioletta A, Jiménez-Ceja LM, Sosale A, Folli F. The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. Arch Med Sci 2013; 9: 936-43.
Aronow WS. Lipid-lowering therapy in older persons. Arch Med Sci 2015; 11: 43-56.
Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11: 1-23.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe